Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
29 authors.
Yuna GuDepartment of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Gangnam-gu, Seoul, South Korea.ORCID 0009-0007-3200-3977
Jihwan YunDepartment of Neurology, Kyung Hee University Hospital, Kyung Hee University College of Medicine, Seoul, South Korea.ORCID 0000-0002-2436-4947
Alexis MoscosoDepartment of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.ORCID 0000-0003-0170-036X
Michael SchöllDepartment of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.ORCID 0000-0001-7800-1781
Daeun ShinDepartment of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Gangnam-gu, Seoul, South Korea.ORCID 0000-0003-4834-1026
Eun Hye LeeDepartment of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Gangnam-gu, Seoul, South Korea.ORCID 0000-0002-4206-6214
Heekyong KangDepartment of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Gangnam-gu, Seoul, South Korea.
Sohyun YimDepartment of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Gangnam-gu, Seoul, South Korea.
Hyunjin JoDepartment of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Gangnam-gu, Seoul, South Korea.
Jun Pyo KimDepartment of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Gangnam-gu, Seoul, South Korea.ORCID 0000-0003-4376-3107
Sung Hoon KangDepartment of Neurology, Korea University Guro Hospital, Korea University College of Medicine, Seoul, South Korea.ORCID 0000-0002-2481-0302
Hee Jin KimDepartment of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Gangnam-gu, Seoul, South Korea.ORCID 0000-0002-3186-9441
Duk L NaDepartment of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Gangnam-gu, Seoul, South Korea.ORCID 0000-0002-0098-7592
Henrik ZetterbergDepartment of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden.ORCID 0000-0003-3930-4354
Kaj BlennowDepartment of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden.ORCID 0000-0002-1890-4193
Fernando Gonzalez-OrtizDepartment of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden.ORCID 0000-0001-7897-9456
Nicholas J AshtonDepartment of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden.ORCID 0000-0002-3579-8804
Hyemin JangDepartment of Neurology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, South Korea.ORCID 0000-0003-3152-1274
Michael W WeinerDepartment of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California, USA.ORCID 0000-0002-0144-1954
Seung Hwan MoonDepartment of Nuclear Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.ORCID 0000-0003-4302-1920
Hanna ChoDepartment of Neurology, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea.ORCID 0000-0001-5936-1546
Jae Yong ChoiDivision of Applied RI, Korea Institute of Radiological & Medical Sciences, Seoul, South Korea.ORCID 0000-0003-1901-8238
Kyung Rok NamDivision of Applied RI, Korea Institute of Radiological & Medical Sciences, Seoul, South Korea.ORCID 0000-0002-8306-2383
Byung Hyun ByunDepartment of Nuclear Medicine, Korea Cancer Center Hospital, Korea Institute of Radiological & Medical Sciences, Seoul, South Korea.ORCID 0000-0002-1146-1916
Su Yeon ParkDepartment of Neurology, Korea Cancer Center Hospital, Korea Institute of Radiological & Medical Sciences, Seoul, South Korea.ORCID 0000-0002-8286-0308
Jeong Ho HaDepartment of Neurology, Korea Cancer Center Hospital, Korea Institute of Radiological & Medical Sciences, Seoul, South Korea.ORCID 0000-0003-1245-1207
Soo Hyun ChoDepartment of Neurology, Chonnam National University Medical School and Chonnam National University Hospital, Gwangju, South Korea.ORCID 0000-0002-4262-1468
Sang Won SeoDepartment of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Gangnam-gu, Seoul, South Korea.ORCID 0000-0002-8747-0122
ADNI and K‐ROAD study groups
Funding
AD Strategic Fund and the Alzheimer's Association #ADSF-21-831376-CAD Strategic Fund and the Alzheimer's Association #ADSF-21-831377-CAD Strategic Fund and the Alzheimer's Association #ADSF-21-831381-CAD Strategic Fund and the Alzheimer's Association #ADSF-24-1284328-CAlzheimer Drug Discovery Foundation #201809-2016862Alzheimer's Association 2021 Zenith Award ZEN-21-848495Alzheimer's Association 2022-2025 SG-23-1038904Bluefield Project, Cure Alzheimer's Fund, Olav Thon Foundation, Erling-Persson Family Foundation, Familjen Rönströms Stiftelse, Stiftelsen för Gamla Tjänarinnor, Hjärnfonden, Sweden #FO2022-0270European Union Joint Program for Neurodegenerative Disorders JPND2019-466-236European Union Joint Programme - Neurodegenerative Disease Research JPND2021-00694European Union's Horizon 2020 research and innovation program under the Marie Skłodowska-Curie 860197European Union's Horizon Europe research and innovation program 101053962European Union's Horizon Europe research and innovation program 101112145European Union's Horizon Europe research and innovation program 101132933Familjen Rönström's Foundation, the Sahlgrenska Academy at the University of Gothenburg, the Västra Götaland Region R&DFuture Medicine 20*30 Project of the Samsung Medical Center #SMX1250081Gates Ventures, the National Research Foundation of Korea RS-2023-00263612Hjärnfonden, Sweden #ALZ2022-0006Hjärnfonden, Sweden #FO2017-0243Korea government (MSIT) No. RS-2021-II212068Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI) RS-2025-02223212Ministry of Health & Welfare and Ministry of Science and ICT, Republic of Korea RS-2020-KH106434MSIT, Republic of Korea 50461-2025National Institute for Health and Care Research University College London Hospitals Biomedical Research Centre, and the UK Dementia Research Institute UKDRI-1003National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIT) RS-2019-NR040057Samsung Medical Center, the "Korea National Institute of Health" 2024-ER1003-01Swedish Alzheimer Foundation #AF-930351Swedish Alzheimer Foundation #AF-939721Swedish Alzheimer Foundation #AF-968270Swedish Alzheimer Foundation #AF-994551Swedish Alzheimer Foundation AF-994900Swedish Brain FoundationSwedish Research CouncilSwedish State Support for Clinical Research #ALFGBG-71320Swedish state under the agreement between the Swedish government and the County Councils, ALF-agreement #ALFGBG-715986Swedish state under the agreement between the Swedish government and the County Councils, ALF-agreement #ALFGBG-965240Swedish state under the agreement between the Swedish government and the County Councils, the ALF-agreement ALFGBG-813971Swedish state under the agreement between the Swedish government and the County Councils, the ALF-agreement ALFGBG-965326the National Institute of Health R01 AG081394-01Wallenberg Centre for Molecular and Translational Medicine
6 · The paper itself
Abstract
introductionWe compared visual assessments and quantification methods for tau positron emission tomography (PET) staging and evaluated plasma biomarkers and cognitive trajectories across amyloid and tau (AT) staging.
methodsTau PET scans from 289 Korea-Registries to Overcome Dementia and Accelerate Dementia Research (K-ROAD) participants were analyzed visually and quantitatively, with validation in the Alzheimer's Disease Neuroimaging Initiative (ADNI) cohort (n = 870). Plasma biomarkers and cognitive measures were evaluated across AT stages.
resultsFreeSurfer without partial volume correction (PVC) achieved the highest area under the curve (AUC) for tau positivity (0.918), based on visual interpretation. The temporal meta-region excelled in moderate tau staging (AUC = 0.856), while the temporoparietal region performed best for advanced staging (AUC = 0.828). Quantification methods detected phosphorylated tau217 changes during intermediate transitions (e.g., A+/T- to A+/Tmod+) more effectively. Plasma biomarkers and cognitive measures progressively changed across AT stages, with consistent results in K-ROAD and ADNI cohorts. DISCUSSION: The complementary strengths of visual and quantification methods enhance tau PET staging by effectively capturing biomarker changes and cognitive trajectories. HIGHLIGHTS: Quantification partially outperformed visual assessments in detecting early tau burdens. Meta-temporal and temporoparietal regions of interest excelled in early and late tau staging. Quantification methods correlated with plasma phosphorylated tau217 and cognitive decline. Findings were validated across two independent cohorts (Korea-Registries to Overcome Dementia and Accelerate Dementia Research and Alzheimer's Disease Neuroimaging Initiative). The study highlights the complementary roles of visual and quantification methods.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Integrating visual assessments and quantification methods for tau PET staging. · full record | OpenQuestion